A clinical trial to compare the safety of moxifloxacin given as infusion in the vein and as tablet to the safety of another treatment regimen in patients with a complicated infection of the abdominal cavity To evaluate the safety of treatment with moxifloxacin (compared to the safety of IV ertapenem followed by PO amoxicillin/clavulanate)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea The primary objective of this study is to show superiority of SH T00658ID over SH D593B with respect to the number of days with dysmenorrheic pain in a defined period, i.e. comparison between two bas...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized phase II study of roniciclib vs placebo in subjects receiving chemotherapy for SCLC Roniciclib és placebo randomizált, II. fázisú vizsgálata kissejtes tüdőrákban szenvedő, kemoterápiával kezelt betegeknél The primary objective is to compare roniciclib with placebo in addition to background treatment with chemotherapy (either cisplatin + etoposide or carboplatin + etoposide) in terms of progression free...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long-term study to collect additional information to evaluate the saftey and tolerability of BAY 63-2521 in different doses To investigate the safety, tolerability, and feasibility of individual titration of BAY 63 2521 according to peripheral systolic blood pressure. In addition, long term safety and tolerability of BAY ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma The primary objective is to evaluate the effect of doxorubicin plus sorafenib or doxorubicin plus placebo on time to progression (TTP) in patients with advanced hepatocellular carcinoma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing 16 mg Candesartan Cilexetil Estudio para probar la efectividad de un comprimido que contiene tanto Nifedipino como Candesartán Cilexetilo, en adultos con presión arterial alta y cuya presión arterial no está bien controlada con comprimidos que contienen Candesartán Cilexetilo 16 mg The primary objective is to demonstrate the efficacy of two FDCs of nifedipine GITS and candesartan cilexetil compared to candesartan cilexetil monotherapy in subjects not adequately controlled on can...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Assess safety and efficacy of BAY 1002670 in subjects with uterine fibroids Evaluar la eficacia y la seguridad de BAY 1002670 en pacientes con miomas uterinos To assess the dose-response relationship of BAY 1002670 in subjects with uterine fibroids. Evaluar la relación dosis-respuesta de BAY 1002670 en pacientes con miomas uterinos.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) Overall Survival

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio multicéntrico, abierto, randomizado, controlado, dos grupos, para evaluar el cumplimiento de la toma diaria en mujeres usuarias de contracepción oral con SHT00186D/BAY 86-5300 (0.02 mg de etinilestradiol como clatrato de betadex, y 3 mg de Drospirenona) en un régimen extendido y flexible, con el apoyo de un dispensador (CADDY) con función de recordatorio, durante 12 meses. (A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months) El objetivo del estudio es evaluar el efecto de la función de recordatorio del dispensador en el cumplimientode la toma diaria de comprimidos, durante 12 meses aproximadamente de tratamiento, en muje...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma To compare progression-free survival (PFS) of randomised metastatic RCC patients receiving sorafenib 400 mg bid versus standard therapy (interferon alpha-2a) as a first-line therapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune